T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Clinical trial NCT02062359 · TERMINATED
Trial details
- NCT number
- NCT02062359
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-01
- Primary completion
- 2016-02-01
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.